7 drugs likely to hit $1B in annual revenue in the next 5 years

Six of the drugs are awaiting FDA approval, and one (tezepelumab) just won approval. Here is a list:

1. Adagrasib: a drug designed to treat colorectal cancer with the KRASG12C mutation, produced by Mirati Therapeutics and Zai Lab.
2. Donanemab: a drug designed to slow cognitive decline, produced by Eli Lilly.
3. Faricimab: a drug designed to treat patients with diabetic macular edema or wet age-related macular degeneration, produced by Roche and Chugai Pharmaceutical.
4. Lecanemab: a drug designed to slow cognitive decline, produced by Eisai and Biogen.
5. Tezepelumab: an asthma drug produced by Amgen and AstraZeneca.
6. Tirzepatide: a drug designed to address weight loss and glycemic control, produced by Eli Lilly.
7. Vutrisiran: a drug designed to treat ATTR, produced by Alnylam Pharmaceuticals.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.